Catalog No.
RHC90701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1.12 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P11836
Applications
ELISA
Form
Liquid
Storage buffer
30mM Histidine, pH 5.8, 10% Sucrose, 0.06% Tween 80.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1332
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910
Continuing progress in radioimmunotherapy for hematologic malignancies., PMID:39609167
CDR grafting and site-directed mutagenesis approach for the generation and affinity maturation of Anti-CD20 nanobody., PMID:38874667
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22., PMID:38596311
Insulin-like Growth Factor 2 (IGF2)-Fused Lysosomal Targeting Chimeras for Degradation of Extracellular and Membrane Proteins., PMID:37899626
Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins., PMID:37552887
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment., PMID:37055223
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura., PMID:36757521
Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation., PMID:36631511
Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells., PMID:36016223
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model., PMID:35499391
Advances in the management of TTP., PMID:35216839
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells., PMID:34429118
COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report., PMID:34327693
[Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura]., PMID:34248125
[Screening, expression and characterization of anti-human CD20 nanobodies]., PMID:33441230
Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody., PMID:33067738
Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly., PMID:32019116
Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential., PMID:31931812
Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes., PMID:29922424
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20., PMID:29574274
Nanobody Based Dual Specific CARs., PMID:29385713
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma., PMID:29054987
Thrombotic thrombocytopenic purpura., PMID:28416507
Selection and characterization of single domain antibodies against human CD20., PMID:27639717
Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas., PMID:23736700
Identification of novel tumor antigens with patient-derived immune-selected antibodies., PMID:18568347